What Is the Life Expectancy of Someone With Polycythemia?

People diagnosed with polycythemia vera (PV) can expect to live for many years, though their lifespan is shorter than the general population’s. A large international study of over 1,500 patients projected a median survival of roughly 14 to 19 years from diagnosis, depending on how long patients had been followed. Those numbers, though, mask enormous variation: a younger person diagnosed without a history of blood clots might live more than two decades, while an older patient with certain risk factors faces a far more compressed timeline. The details of who lands where on that spectrum are worth understanding.

What the Headline Survival Numbers Mean

The most cited survival data for PV comes from an international study published in 2013 that tracked 1,545 patients across seven centers. For the full cohort, projected median survival was about 19 years. But the researchers noted something important: when they restricted the analysis to the center with the most mature follow-up data (where nearly half the patients had been followed to death), median survival dropped to about 14 years, and the survival disadvantage compared to an age- and sex-matched general population was statistically clear.¹ The gap between 14 and 19 years is not a contradiction; it reflects the reality that newer cohorts with shorter follow-up tend to overestimate survival because many patients are still alive when the data is analyzed.

An earlier study put the 15-year survival rate at about 65%, with mortality roughly 1.6 times higher than the general population.² A U.S. population-based analysis found a similar picture, with PV patients facing about a 90% increased risk of death from all causes compared to the general population.³ So the honest answer is that PV shortens life, but for most people it is a disease measured in decades, not months or a handful of years.

Why Age Matters More Than Almost Anything Else

If you or someone you know has been diagnosed, the single most powerful predictor of how long you’ll live with PV is how old you were at diagnosis. The same international study that produced those headline numbers developed a risk-scoring system built around three factors: age, white blood cell count, and history of blood clots in veins. Age dominated the model. Being 67 or older at diagnosis carried the heaviest weight, followed by the 57-to-66 range. A high white blood cell count and a history of venous thrombosis each added smaller but meaningful risk.¹

The resulting risk groups had strikingly different outlooks. Patients in the low-risk category (younger, normal white count, no venous clots) had a median survival of 26 years. Intermediate-risk patients lived a median of 15 years. High-risk patients, predominantly those over 67, had a median survival of about 8 years.¹ That 26-versus-8-year gap underscores why a single median survival number for “PV” can be misleading. The disease’s impact is heavily shaped by who gets it and when.

Standard clinical risk assessment for deciding how aggressively to treat PV is simpler: it relies on whether a patient is over 60 and whether they have had a prior blood clot.⁴ The more detailed three-factor model adds precision, but the message is consistent: age at diagnosis is the dominant variable.

What People With PV Actually Die From

PV doesn’t typically kill through a single dramatic pathway. The U.S. population study covering 2001 to 2017 found that about three-quarters of excess deaths in PV patients were due to non-cancer causes. Heart disease was by far the largest contributor, responsible for the greatest number of excess deaths per 10,000 person-years. Deaths from cerebrovascular disease (strokes), chronic lung disease, infections, and liver disease were also elevated, ranging from roughly two to three times the expected rate in the general population.³

On the cancer side, the biggest threat was transformation to a blood cancer called acute myeloid leukemia (AML) or a pre-leukemic state (myelodysplastic syndrome). The risk of dying from these was roughly 13 times higher than in the general population.³ The practical takeaway is that cardiovascular events are the most common way PV shortens life, while blood cancer transformation is rarer but extremely dangerous when it occurs.

When PV Transforms Into Something Worse

PV can evolve into two more serious conditions over time: myelofibrosis (scarring of the bone marrow) and acute leukemia. Both are uncommon but carry major survival consequences.

The risk of myelofibrosis grows over time. A meta-analysis of patients treated with hydroxyurea estimated the chance of developing myelofibrosis at roughly 5% at five years and about a third at ten years (estimates that shift with age at follow-up start). Once someone develops post-PV myelofibrosis, the outlook changes: a study of 68 such patients found a median survival of about 5.7 years from the point of transformation, with anemia at the time of that diagnosis being a key adverse factor.⁵⁶

Leukemic transformation is less common but grimmer. The annual rate of transformation to acute leukemia runs at roughly 0.4%, with a slight tendency to increase after about eight years of disease.⁵ If transformation occurs, survival is measured in months, not years. A study of 23 PV patients who developed acute leukemia found a median survival of about three months from that transformation, with no significant difference between patients who received intensive treatment and those who received comfort-focused care.⁷ Most of these patients were older (78% were over 60) and had high-risk genetic abnormalities at the time of leukemic change.⁷

How Treatment Shapes the Outlook

The backbone of PV management is straightforward: regular phlebotomy (blood removal) to keep the hematocrit below 45%, combined with low-dose aspirin.⁸ This applies to all patients regardless of risk category.⁹ The hematocrit target is well-established and is one of the clearest interventions to reduce the risk of blood clots and cardiovascular events.

For patients considered high-risk, additional medications are used to bring blood counts down further. Hydroxyurea is the most commonly prescribed of these. A propensity-matched study comparing hydroxyurea to phlebotomy alone found that hydroxyurea reduced the rate of fatal and non-fatal cardiovascular events (about 3 events per 100 person-years versus nearly 6 with phlebotomy alone), and myelofibrosis transformation occurred only in the phlebotomy-only group during the follow-up period.¹⁰

For patients who don’t respond to or can’t tolerate hydroxyurea, ruxolitinib (a JAK inhibitor) is an option. In a randomized trial, five-year survival was about 92% with ruxolitinib and 91% with best available therapy, suggesting no major survival difference over that timeframe.¹¹ However, ruxolitinib was associated with more frequent molecular responses (reductions in the disease-driving JAK2 mutation), which in turn were linked to better progression-free survival and overall survival within the trial.¹² A separate real-world study with a median follow-up of about three and a half years found no survival or progression differences between ruxolitinib and best available therapy, suggesting that outside of clinical trials, the survival benefit is hard to demonstrate.¹³ In short, treatment clearly reduces complications and likely extends life, but no current drug is curative.

The Role of JAK2 Mutation Burden

Nearly all PV patients carry a mutation in the JAK2 gene, but the fraction of blood cells carrying that mutation (the allele burden) varies from person to person and can change over time. That burden appears to matter for prognosis. A meta-analysis found that patients with a higher allele burden had significantly greater odds of developing splenomegaly, blood clots, myelofibrosis, and acute leukemia.¹⁴

A study from South Korea found a sharper picture: among PV patients followed for eight years, those with an allele burden below 58% had 100% overall survival, while those at or above 58% had survival of about 67%. Transformation-free survival showed a similar split.¹⁵ Economic modeling based on these patterns estimated that patients with lower allele burdens (below 50%) lived roughly two years longer on average than those with burdens at or above 50%.¹⁶ This is one reason treatments that reduce the allele burden attract interest: if the molecular fire can be turned down, the long-term risks may shrink with it.

PV in Younger Patients

Most people with PV are diagnosed in their 60s or later, but it can occur in people under 40. The prognosis for younger patients is better in absolute terms but paradoxically worse when measured against peers. An Italian study following young PV patients found that overall survival at 20 years was 62%, and median survival exceeded 23 years. That sounds encouraging until you compare it to the general population: the standardized mortality ratio was 5.3, meaning these patients were more than five times as likely to die as age-matched people without PV.¹⁷ The dominant causes of death in this younger group were progression to leukemia or myelofibrosis, followed by vascular events. In other words, young patients live a long time, but PV erodes their expected lifespan more severely in relative terms than it does for an older patient who already has a shorter life expectancy to begin with.

Cardiovascular Risk Factors and Their Amplifying Effect

PV raises blood clot and cardiovascular risk on its own, but standard cardiovascular risk factors like high blood pressure, high cholesterol, obesity, and smoking stack on top of that elevated baseline.¹⁸ This is not a theoretical concern: a study of PV and essential thrombocythemia patients found a significant correlation between the number of cardiovascular risk factors a patient carried and their survival.¹⁹ Hypertension specifically has been linked to a higher risk of blood clots in PV patients on multivariable analysis.²⁰

Because heart disease is the leading non-cancer cause of excess death in PV, aggressive management of blood pressure, cholesterol, and smoking cessation is not just good general-health advice for these patients; it may be as consequential for survival as any PV-specific drug. This is an area where patients have real agency, and yet it gets less attention than discussions about which medication to use.

Primary Versus Secondary Polycythemia

Not all elevated red blood cell counts are PV. Secondary polycythemia (also called secondary erythrocytosis) describes a high red blood cell count driven by an underlying cause like chronic lung disease, obstructive sleep apnea, or living at high altitude. The distinction matters a great deal for life expectancy. A study comparing mortality in both groups found that among patients who died during a 16-year follow-up period, those with secondary polycythemia had a significantly shorter median time from diagnosis to death: about 21 months, compared to roughly 43 months for primary PV.²¹ The researchers attributed this to the severity of the conditions causing the secondary polycythemia, such as advanced COPD or heart failure, which carry their own mortality burden independent of the elevated blood counts.

If you’ve been told your red blood cell count is high, understanding whether you have true PV (driven by the JAK2 mutation) or a secondary cause is essential. The prognosis, the treatment, and the day-to-day management are different. Secondary polycythemia is treated by addressing the underlying condition, and the life expectancy outlook depends mostly on that condition rather than on the blood count itself.

Pregnancy and PV

PV is uncommon in women of childbearing age, but when it does occur, pregnancy adds a layer of risk. The disease is already associated with a heightened tendency to form blood clots, and pregnancy itself is a pro-clotting state. The combination creates elevated risk for both the mother and the fetus, including placental clots that can compromise the pregnancy.²² Management typically requires close coordination between hematologists and obstetricians, with antiplatelet therapy and careful monitoring of blood counts. While pregnancy does not fundamentally change the long-term life expectancy outlook for the mother, it represents a high-risk window that demands careful management.

How Real-World Patients Differ From Trial Populations

One caveat worth keeping in mind when interpreting any of these survival figures: the patients enrolled in landmark studies tend to be younger and healthier than the average person diagnosed with PV in everyday clinical practice. A chart review of over 1,400 PV patients treated in real-world settings found a median age of about 72 at the time of reporting and 63.5 at diagnosis, with age being the primary driver of high-risk classification for nearly 85% of patients.²³ This matters because the encouraging survival medians from large international trials may overrepresent younger patients and undercount the typical comorbidities that older patients carry. Your hematologist’s assessment of your individual risk factors will give you a more realistic picture than any published median can.